Since its establishment, the Fondazione Italiana Linfomi (FIL) has conducted or contributed to the management of over 100 clinical trials dedicated to the treatment of lymphomas.
Clinical trials are scientific studies that evaluate new therapeutic strategies, such as innovative drugs or new combinations and dosages of treatments already used in clinical practice. They may also involve the collection and analysis of epidemiological data, including disease incidence, causes, diagnostic approaches, and treatments used.
Each clinical study is described in a document called a protocol, which defines the research objectives and the procedures for conducting the study.
The goal of clinical research is to identify increasingly effective and less toxic therapies, improve the quality of care, and translate research findings into clinical practice.
FIL clinical trials
FIL studies are conducted simultaneously across multiple onco-hematology centers in Italy under the responsibility of a scientific coordinator, the Principal Investigator (PI).
All trials are carried out in compliance with Italian clinical research regulations and are approved by Ethics Committees and AIFA (Italian Medicines Agency), ensuring scientific, legal, and ethical standards.
Before participating in a clinical trial, patients receive detailed information from the physician responsible at their treatment center. Only after receiving all necessary explanations can they freely decide whether to participate by signing an informed consent form.
Participation may provide access to innovative drugs, new diagnostic techniques, or the best available treatments in the onco-hematology field at the time of the study.
It is important to note that participation in a clinical trial does not necessarily guarantee a positive outcome, but it does ensure access to treatments that are at least equivalent to standard clinical practice.
These studies contribute significantly to the advancement of lymphoma research through the collection of clinical data (always anonymized), statistical analysis, and publication of results in international scientific journals.
How to Participate in a FIL Clinical Trial
Clinical trials are not suitable for all patients, even those with the same disease, as each protocol includes specific eligibility criteria.
It is important to emphasize that patients are not “guinea pigs”: clinical trials follow strict regulations designed to ensure maximum patient protection.
The physician responsible for the study at the hematology center will:
- inform the patient about the study objectives
- explain the protocol and treatment procedures
- describe potential benefits and possible side effects
- answer all questions and address any concerns
Patients are given all the time they need to consider the information and decide whether to participate.
Participation is entirely voluntary. Patients may withdraw their consent at any time without penalty and without losing access to standard medical care.
Withdrawing from a study does not affect the quality of future medical care. If a patient decides to leave a study, the physician will explain the safest way to discontinue any ongoing treatment.
Participation in a clinical trial involves no cost and no financial compensation for the patient, who will be closely monitored throughout all phases of the study in accordance with the protocol.